An independent jury of experts annually selects the laureates of the Swiss Biotech Success Stories.
Undergrad at ETH in Zürich with Master in Immunology. PhD at the Biocenter in Basel in biochemistry, and then Member of the Basel institute for immunology. Followed by Hoffmann-La Roche Ltd as a Global discovery portfolio manager. Further as Fundamental analyst at BT&T asset management, and as a freelance consultant. Established Biopolo Ticino where he also participated in the creation of the Swiss marketing platforms Swiss Biotech and Swiss Medtech. Then Director Business Development at Actelion, and NovImmune.
MD (1980) and a Neuroscientist (1983) at the Universities of Geneva and Fribourg in Switzerland. Faculty positions at Brown University and the University of Lausanne prior to joining EPFL.He has received numerous honors, including the Robert Bing Prize of the Swiss Academy of Medicine and the Pfizer Foundation Prize for Clinical Neurosciences. He is a member of the scientific committee of the Italian Institute of Technology and a member of the Singapore Biomedical Sciences International Advisory Council. Prof. Aebischer is a member of the Board of Lonza, Nestlé and Logitech and a founder of three biotech companies. He chairs the Novartis Venture Fund and is a Senior Partner of NanoDimension-III.
Head Business Development and Licensing at Vifor Pharma in Switzerland, President Swiss Healthcare Licensing Group and member of the European Pharma Licensing Council, Gabrielle is passionate about health & well-being. She has more than 20 years of experience in the pharmaceutical industry and held various leading positions in finance, marketing and business development. Her experience at the medical research foundation completes this profile in the field of not-for-profit organization and tech transfers. Driven by an entrepreneurial spirit, she connects quickly and aims to establish long term partnering relationships where mutual respect matters.
Head private equity
at HBM Partners
Over 25 years experience in the Venture Capital Industry. PhD ETH Zurich in Natural Sciences and Industrial Engineering. Previously in management functions at Innoventure, Credit Suisse, Apax and Vontobel. Board member of Westmed and Reha Technology.
at Mirabaud Basel
at NZZ am Sonntag
At NZZ am Sonntag, Birgit Voigt covers pharmaceutical as well as biotech companies and industry since 2002. Her education and positions include: business correspondent for “Cash” in California; knight fellowship in journalism, Stanford; head business section “Tages-Anzeiger”. She has a master in economics from the University of Zurich and in political science from Virginia Tech, USA.
Partner, biotech/medtech leader GSA
at Ernst & Young
Jürg Zürcher heads EY’s Biotechnology Sector in Europe, the Middle East, India and Africa. His main focus is the life sciences sector and he is also active in the venture capital business. Jürg Zürcher provided the Swiss Federal Government with a comprehensive analysis of the state of biotechnology in Switzerland. He also supported the introduction of the first Swiss Biotech Report in March 2004.
Thomas Staffelbach is an experienced communications director, former head of communications and investor relations of several listed and private companies. Thomas is passionate about innovation and the people behind it. For almost 15 years, he has been advising biotech and pharmaceutical companies to position the medical and commercial potential of their innovations.